ASMB
Assembly Biosciences Inc.
$24.78
+$0.32(+1.31%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
$186.81M
Volume
236.42K
52W Range
$7.75 - $27.17
Target Price
$38.25
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | $9.0M | $14.8M | $16.0M | $79.1M | $6.3M | $153.0K | $7.2M | $28.5M | ||
| Total Revenue | -- | -- | $9.0M | $14.8M | $16.0M | $79.1M | $6.3M | $153.0K | $7.2M | $28.5M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $-4.6M | -- | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | $9.0M | -- | -- | $79.1M | $6.3M | $153.0K | $7.2M | $28.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-29.7M | $-45.3M | $-61.2M | $-107.5M | $-118.7M | $143.9M | $138.9M | $94.1M | $71.8M | $73.9M | ||
| Research & Development | $18.4M | $33.1M | $44.2M | $72.7M | $85.8M | $106.8M | $68.5M | $70.0M | $48.9M | $55.9M | ||
| Research Expense | $18.4M | $33.1M | $44.2M | $72.7M | $85.8M | $106.8M | $68.5M | $70.0M | $48.9M | $55.9M | ||
| Selling, General & Administrative | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | $37.1M | $28.8M | $24.1M | $22.9M | $18.0M | ||
| General & Administrative Expenses | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | $37.1M | $28.8M | $24.1M | $22.9M | $18.0M | ||
| Salaries & Wages | $-7.9M | $-5.0M | $-8.6M | $-28.5M | $-20.6M | -- | -- | -- | $5.1M | $3.1M | ||
| Depreciation & Amortization | $-65.0K | $-80.3K | $-219.0K | $-600.0K | $-500.0K | $700.0K | $500.0K | $500.0K | $500.0K | -- | ||
| Depreciation & Amortization | $-65.0K | $-80.3K | $-219.0K | $-600.0K | $-500.0K | $700.0K | $500.0K | $500.0K | $500.0K | -- | ||
| Other Operating Expenses | -- | -- | -- | $-107.5M | $-118.7M | $-747.0K | $-663.0K | $-672.0K | $-575.0K | $-711.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-29.7M | $-45.3M | $-61.2M | $-107.5M | $-118.7M | $-64.8M | $-132.7M | $-94.1M | $-64.6M | $-45.4M | ||
| EBITDA | $-28.4M | $-44.8M | $-51.6M | $-89.2M | $-99.6M | $-64.1M | $-90.6M | $-92.4M | $-64.2M | $-43.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $1.2M | $1.5M | $983.0K | $3.1M | $4.3M | $2.6M | $302.0K | $1.0M | $3.5M | $5.6M | ||
| Net Non-Operating Interest Income/Expense | $1.2M | $1.5M | $983.0K | $3.1M | $4.3M | $2.6M | $302.0K | $1.0M | $3.5M | $5.6M | ||
| Gain on Sale of Securities | $-27.0K | $-1.1M | $-615.0K | $231.0K | $4.0K | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $27.0K | $1.1M | $-8.4M | $-14.8M | $-16.0M | $-37.0M | $22.7M | -- | $-2.7M | $-28.3M | ||
| Other Special Charges | -- | -- | $9.0M | $14.8M | $16.0M | $37.0M | $6.3M | -- | $2.7M | $28.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $-2.1M | $3.8M | $1.6M | $1.1M | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | $2.1M | $-3.8M | $-41.6M | $-1.1M | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | $41.6M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-28.5M | $-44.9M | $-51.9M | $-89.7M | $-98.4M | $-64.8M | $-91.0M | $-93.1M | $-64.6M | $-39.8M | ||
| Pre-Tax Income | $-28.5M | $-44.9M | $-51.9M | $-89.7M | $-98.4M | $-62.2M | $-132.4M | $-93.1M | $-61.2M | $-39.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $-617.7K | $-9.1M | $1.1M | $-774.0K | -- | $-2.5M | -- | $33.0K | $330.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
| Net Income (Continuing Operations) | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
| Net Income (Discontinued Operations) | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
| Net Income (Common Stockholders) | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-39.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-29.7M | $-45.3M | $61.2M | $-107.5M | $-118.7M | $143.9M | $138.9M | $94.1M | $71.8M | $73.9M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $15.7M | $17.2M | $17.8M | $22.8M | $26.3M | $3.0M | $3.6M | $4.0M | $4.6M | $6.0M | ||
| Average Shares Outstanding (Diluted) | $15.7M | $17.2M | $17.8M | $22.8M | $26.2M | $3.0M | -- | $4.0M | $4.6M | $6.0M | ||
| Shares Outstanding | $17.2M | $17.3M | $20.3M | $25.5M | $32.6M | $3.2M | $4.0M | $4.3M | $5.5M | $7.5M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-21 | $-36 | $-23.04 | $-13.38 | $-6.69 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-21 | $-36 | $-23.04 | $-13.38 | $-6.69 | ||
| Diluted EPS | $-1.81 | $-2.57 | $-2.41 | $-3.98 | $-3.72 | $-21 | $-36 | $-23.04 | $-13.38 | $-6.69 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-23.04 | $-13.38 | $-6.69 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | $37.1M | $28.8M | $24.1M | $22.9M | $18.0M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $700.0K | $29.0M | -- | -- | -- | ||
| Rent And Landing Fees | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | $-2.1M | $3.8M | $1.6M | $1.1M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASMB | $24.78 | +1.3% | 236.42K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Assembly Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW